Loading
A phase 2 trial of Disitamab vedotin, RC148 and Toripalimab in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting.
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer is a phase 2 interventional study registered as NCT06642545 by RemeGen Co., Ltd., with 40 participants planned, started 2025-02-10 and due to reach its primary completion in 2026-10-01. Interventions recorded: Disitamab Vedotin, RC148, Albumin-bound Paclitaxone and Toripalimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
Shares RC148, RemeGen, Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/